Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY:JNJ)

237.82 -7.48 (-3.05%)
Streaming Delayed Price Updated: 11:32 AM EST, Mar 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
2 Top Defensive ETFs That Prioritize Stability Over Excitement ↗
If you're worried about downside risk right now, here are two smart choices. 
Via The Motley Fool
Topics Artificial Intelligence ETFs World Trade
News headline image
ImmunityBio (IBRX) Shares Plummet Despite Piper Sandler Price Target Hike and 700% Revenue Growth
In a classic case of "selling the news," shares of ImmunityBio, Inc. (NASDAQ: IBRX) took a sharp dive on Wednesday, March 4, 2026, plummeting over 13% to close at $9.02. The sell-off came as a surprise... 
Via MarketMinute
Topics Earnings Economy
News headline image
The Return of the Titans: M&A Volume Set to Surge 20% in 2026 Amidst "Animal Spirits"
As of March 4, 2026, the global financial landscape is witnessing a seismic shift in corporate strategy. After years of cautious maneuvering and high interest rates, the "animal spirits" of the... 
Via MarketMinute
Topics Artificial Intelligence Economy World Trade
News headline image
How to Spot Winning Innovation ↗
Author Lorraine Marchand stops by to chat. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Middleby Is Spinning Off Its Food Processing Segment After a $540 Million Asset Sale. Can the Breakup Close Its Valuation Gap? ↗
Middleby is splitting up, and the sum-of-the-parts math looks promising if margins cooperate. 
Via The Motley Fool
News headline image
2 Reasons I'd Happily Hold Johnson & Johnson Through Any Market Crash ↗
The company has proven its resilience in the past. 
Via The Motley Fool
News headline image
Argenx (ARGX) 2026 Feature: The Anatomy of a Biotech Powerhouse Transitioning to Profitability
As of February 26, 2026, the biotechnology sector is witnessing a historic maturation. For years, the industry narrative was dominated by high-burn, pre-revenue innovators searching for a "blockbuster"... 
Via Finterra
Topics Earnings Economy Intellectual Property
News headline image
ACR Alpine Capital Research Buys 1 Million Shares of Arrow Electronics Stock ↗
Arrow Electronics is a global distributor delivering electronic components and enterprise IT solutions to industrial and commercial clients. 
Via The Motley Fool
News headline image
Boring Is Beautiful: Why Johnson & Johnson Is Beating the Tech Sector ↗
Via MarketBeat
News headline image
Is Johnson & Johnson Stock Outperforming the Nasdaq?
Though Johnson & Johnson has outperformed the broader Nasdaq Composite over the past year, Wall Street analysts remain cautiously optimistic about the stock’s prospects. 
Via Barchart.com
Topics Stocks World Trade
News headline image
Kenvue Defies Market Headwinds with Q4 Earnings Beat as Kimberly-Clark Merger Looms
In a pivotal moment for the consumer health landscape, Kenvue (NYSE: KVUE) has reported a robust set of fourth-quarter results for 2025, signaling a successful turnaround and strategic resilience just... 
Via MarketMinute
Topics Earnings Economy World Trade
News headline image
Johnson & Johnson: This Dividend King Could Anchor a Millionaire Retirement Portfolio ↗
It's about striking that perfect balance between chasing growth and protecting what you already have. 
Via The Motley Fool
Topics Retirement
News headline image
The Only Healthcare Stock I'd Buy and Never Sell Might Be Johnson & Johnson ↗
Johnson & Johnson stock is boring -- in a good way. 
Via The Motley Fool
News headline image
Economic Stagnation: Q4 2025 GDP Misses Mark as Government Shutdown Hangs Heavy Over 2026 Outlook
The U.S. economy faced a sobering reality check on Friday as the Bureau of Economic Analysis (BEA) released its preliminary reading for the fourth quarter of 2025. Gross Domestic Product (GDP) grew at... 
Via MarketMinute
Topics Earnings Economy
Friday's session: gap up and gap down stock in the S&P500 index ↗
Via Chartmill
News headline image
JNJ Stock Rises As Drugmaker Reportedly Eyes Orthopedics Segment Sale For Up To $20B ↗
Bloomberg reported, citing people familiar with the matter, that DePuy Synthes could be valued at more than $20 billion in a sale. 
Via Stocktwits
News headline image
Health Care Sector (XLV) Shows Resilience Amid Tech Volatility and Strong Jobs Data
As the broader market grappled with a violent valuation reset in the technology sector, the health care industry emerged as a critical anchor for investors in early 2026. The Health Care Select Sector... 
Via MarketMinute
Topics Artificial Intelligence ETFs Earnings
News headline image
FDA Grants Breakthrough Status To Johnson & Johnson's Cancer Drug For Advanced Head and Neck Cancer ↗
FDA grants Breakthrough Therapy status to Rybrevant for advanced cancer while Trellus Health extends IBD support contract. 
Via Benzinga
News headline image
Behind the Scenes of Johnson & Johnson's Latest Options Trends ↗
 
Via Benzinga
News headline image
Johnson & Johnson's New FDA Approval Lets Lung Cancer Patients Switch To Monthly Dosing Sooner ↗
FDA approves monthly dosing for J&J's Rybrevant Faspro with Lazcluze, offering faster, easier treatment for EGFR lung cancer. 
Via Benzinga
News headline image
The Seven-Thousand Siege: S&P 500’s Historic Breach and the Great Tech Pivot of 2026
In a watershed moment for global equity markets, the S&P 500 (INDEXSP:.INX) briefly conquered the psychological 7,000-point milestone in late January 2026, marking the fastest 1,000-point ascent in the... 
Via MarketMinute
Topics Artificial Intelligence ETFs Earnings
News headline image
ASCO GU 2026: Merck and Protara Poised to Disrupt Bladder and Kidney Cancer Standards
As the oncology community prepares to descend upon San Francisco for the 2026 ASCO Genitourinary (GU) Cancers Symposium from February 26–28, investors and clinicians alike are bracing for data that... 
Via MarketMinute
Topics Intellectual Property
News headline image
Jury: Johnson & Johnson Liabile in Case Linking Baby Powder to Cancer ↗
On Friday, a Pennsylvania state-court jury in Philadelphia ordered Johnson & Johnson (NYSE: JNJ) to pay $250,000 to the family of Gayle Emerson, finding the company liable in a case blaming its talc... 
Via Benzinga
News headline image
Volatility Returns to Wall Street: VIX Surges 18% as AI Fatigue Triggers Massive Three-Day Sector Rotation
The U.S. equity markets faced a grueling three-session losing streak ending Friday, February 13, 2026, as a wave of "AI capex fatigue" and disappointing corporate guidance sent investors scurrying for... 
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
News headline image
"Blowout" Jobs Report Ignites 2026 Growth Hopes as Unemployment Hits 4.3% Floor
The U.S. labor market kicked off 2026 with an unexpected surge, as the January nonfarm payrolls report shattered analyst expectations and provided a much-needed jolt to the economic outlook. Adding... 
Via MarketMinute
Topics Artificial Intelligence Economy Workforce
News headline image
The Great Rebound: US M&A Market Ignites as Megadeals Surge 111% in AI-Driven Supercycle
The United States merger and acquisition (M&A) landscape has entered a transformative era in early 2026, marking a definitive end to the deal-making drought that plagued the previous two years. Driven... 
Via MarketMinute
Topics Artificial Intelligence Economy Energy
News headline image
Is Johnson & Johnson a Buy, Sell, or Hold in 2026? ↗
This reliable dividend payer may be just what the doctor ordered. 
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property Lawsuit
News headline image
5 Stocks and ETFs to Help Shield Your Portfolio During Volatility ↗
Via MarketBeat
Topics ETFs
News headline image
Johnson &amp; Johnson Reports 90% AFib Freedom In Early Heart Device Study ↗
Johnson & Johnson shared early AFib study results showing 90% success and no safety issues, but the stock lagged as healthcare stocks outperformed broader markets. 
Via Benzinga
News headline image
What is Considered a Good Stock Dividend? 2 Healthcare Stocks That Fit the Bill. ↗
These companies pay very healthy dividends. 
Via The Motley Fool
Topics Bonds
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.